Notably, although genomic sequencing of 110 human AML cases did not reveal point mutations or small insertions/deletions within the enhancer ([24] and T. Ley, personal communication), ChIP-Seq demonstrated that the RUNX1-ETO AML oncoprotein binds specifically at the homologous +42 kb CEBPA enhancer, but not the CEBPA promoter, in two patient samples and in the Kasumi-1 cell line [25]. Here, RUNX1 is linked to acute myeloid leukemia.